Karlo Vidovic

Mr. Karlo Vidovic


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2025 in Cells
Verified
Journal Article
Open access
PDF file
ASAbdul Shakerdi
Abdul Shakerdi
EFEmma Finnegan
Emma Finnegan
YSYin Yin Sheng
Yin Yin Sheng
KVKarlo Vidovic
Karlo Vidovic
JLJessica M Logan
Jessica M Logan
PTPrerna Tewari
Prerna Tewari
Epithelial-mesenchymal transition (EMT) and inflammasome signalling are intercon-nected processes which underpin tumour progression, metastasis, and therapeutic re-sistance. Inflammasomes such as NLRP3 encourage pro-inflammatory states (IL-1β, IL-18, NF-κB) and the activation of signalling pathways like TGF-β that promote mes-enchymal traits crucial for EMT. EMT transcriptional programmes can then in turn modulate the inflammasome via NF-κB/TGF-β signalling, creating self-perpetuating mechanisms of cellular plasticity and dysregulated therapeutic response. We have re-viewed the mechanistic evidence for EMT–inflammasome crosstalk in cancer and discussed the potential therapeutic implications. The function of the EMT-inflammasome axis is clearly context-dependent, with the cancer type, stage, and the complexity of the tumour microenvironment heavily contributing. The crosstalk between EMT and the inflammasome is an overlooked mechanism of tumour evolution, and targeting inflammasomes like NLRP3, or their downstream signalling pathways, offers a promising therapeutic avenue, with the objective of inhibiting metastasis and overcoming drug resistance.

12 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAbdul Shakerdi
Abdul Shakerdi
EFEmma Finnegan
Emma Finnegan
YSYin Yin Sheng
Yin Yin Sheng
KVKarlo Vidovic
Karlo Vidovic
JLJessica M Logan
Jessica M Logan
PTPrerna Tewari
Prerna Tewari
Epithelial-mesenchymal transition (EMT) and inflammasome signaling are interconnected processes which underpin tumour progression, metastasis, and therapeutic resistance. Inflammasomes such as NLRP3 encourage pro-inflammatory states (IL-1β, IL-18, NF-κB) and the activation of signalling pathways like TGF-β that promote mesenchymal traits crucial for EMT. EMT transcriptional programs can then in turn modulate the inflammasome via NF-κB/TGF-β signaling, creating self-perpetuating mechanisms of cellular plasticity and dysregulated therapeutic response. We have reviewed the mechanistic evidence for EMT–inflammasome crosstalk in cancer and discussed the potential therapeutic implications. The function of the ENT-inflammasome axis is clearly context-dependent, with the cancer type, stage, and the complexity of the tumour microenvironment heavily contributing. The between EMT and the inflammasome is an overlooked mechanism of tumour evolution and targeting inflammasomes like NLRP3, or their downstream signalling pathways offer a promising therapeutic avenue, with the therapeutic objective of reducing metastasis and overcoming drug resistance.